Mirum Pharmaceuticals (MIRM) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Mirum Pharmaceuticals (NASDAQ: MIRM):

• 3/4/2026 – Mirum Pharmaceuticals was given a new $126.00 price target by Evercore Inc.
• 2/28/2026 – Mirum Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “hold”.
• 2/26/2026 – Mirum Pharmaceuticals had its price target lowered by Leerink Partners from $120.00 to $118.00. They now have an “outperform” rating on the stock.
• 2/26/2026 – Mirum Pharmaceuticals had its “outperform” rating reaffirmed by Evercore Inc.
• 2/26/2026 – Mirum Pharmaceuticals had its price target raised by TD Cowen from $115.00 to $117.00. They now have a “buy” rating on the stock.
• 2/26/2026 – Mirum Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $130.00 to $128.00. They now have an “outperform” rating on the stock.
• 2/26/2026 – Mirum Pharmaceuticals had its price target raised by Stifel Nicolaus from $98.00 to $125.00. They now have a “buy” rating on the stock.
• 2/26/2026 – Mirum Pharmaceuticals had its price target lowered by Citizens Jmp from $140.00 to $132.00. They now have a “market outperform” rating on the stock.
• 2/17/2026 – Mirum Pharmaceuticals is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $130.00 price target on the stock.
• 2/17/2026 – Mirum Pharmaceuticals is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $130.00 price target on the stock.
• 1/30/2026 – Mirum Pharmaceuticals had its price target raised by Morgan Stanley from $95.00 to $123.00. They now have an “overweight” rating on the stock.
• 1/26/2026 – Mirum Pharmaceuticals had its price target raised by HC Wainwright from $102.00 to $130.00. They now have a “buy” rating on the stock.
• 1/22/2026 – Mirum Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/20/2026 – Mirum Pharmaceuticals had its “outperform” rating reaffirmed by Evercore Inc. They now have a $101.00 price target on the stock.
• 1/17/2026 – Mirum Pharmaceuticals was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 1/13/2026 – Mirum Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $102.00 price target on the stock, up from $81.00.
• 1/12/2026 – Mirum Pharmaceuticals had its “buy” rating reaffirmed by TD Cowen.

Insider Activity at Mirum Pharmaceuticals

In related news, CEO Christopher Peetz sold 9,108 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $940,856.40. Following the sale, the chief executive officer owned 160,294 shares in the company, valued at $16,558,370.20. The trade was a 5.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Eric Bjerkholt sold 1,053 shares of the stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $96.19, for a total value of $101,288.07. Following the completion of the transaction, the chief financial officer owned 43,741 shares of the company’s stock, valued at $4,207,446.79. This represents a 2.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 45,136 shares of company stock worth $4,352,029 over the last 90 days. 14.36% of the stock is currently owned by company insiders.

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.